Analysts Rate Sesen Bio Inc Stock as a “Hold” Despite -1.96% Loss This Week and -43.82% Drop Over Last Year
December 29, 2022
Trending News 🌥️
Sesen Bio ($NASDAQ:SESN) Inc is a biopharmaceutical company focused on developing targeted fusion protein therapeutics for the treatment of patients with cancer. The company’s portfolio includes Vicinium, an antibody-drug conjugate that is being evaluated in Phase 3 clinical trials for the treatment of non-muscle invasive bladder cancer. This rating indicates that analysts believe investors should neither buy or sell the stock at the current time. The answer to this question depends on the individual investor’s risk tolerance and investment goals.
Investors who are more aggressive may be willing to take on the risk associated with a volatile stock like Sesen Bio Inc in order to potentially benefit from bigger gains in the future. On the other hand, a more conservative investor may be more comfortable avoiding Sesen Bio Inc stock at this point in time. Overall, it is up to investors to decide if Sesen Bio Inc is a good buy for them.
Market Price
At the time of writing, news coverage has been mostly mixed. On Friday, Sesen Bio stock opened at $0.5 and closed at $0.5, up by 1.9% from the prior closing price of 0.5. The company’s future performance will depend on a range of factors, including its ability to increase revenues, improve margins and reduce expenses.
Additionally, Sesen Bio Inc’s ability to develop new products in its core markets and expand into other markets could play a pivotal role in its future success. Ultimately, investors will need to consider all the available information before making any decisions about investing in Sesen Bio Inc stock. Investors should keep a close eye on the company’s progress and any updates that may affect its stock price before making any investment decisions. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sesen Bio. More…
| Total Revenues | Net Income | Net Margin |
| 60 | -3.37 | -23.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sesen Bio. More…
| Operations | Investing | Financing |
| 9.61 | -113.73 | 0 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sesen Bio. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 199.72 | 34.7 | 0.81 |
Key Ratios Snapshot
Some of the financial key ratios for Sesen Bio are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 197.9% | – | -43.3% |
| FCF Margin | ROE | ROA |
| 16.0% | -10.6% | -8.1% |
VI Analysis
Investing in a company’s stock is a long-term endeavor and careful consideration of the company’s fundamentals is essential. VI App allows investors to analyze a company’s fundamentals quickly and easily. One example is SESEN BIO, for which VI App has given a high-risk rating. This rating is based on four risk warnings in the company’s income sheet, balance sheet, cashflow statement, and financial journal. It is important to note that a high-risk rating does not necessarily mean that the company is an unsuitable investment option. However, it does indicate that potential investors must be aware of the risks associated with investing in SESEN BIO and take them into account when making decisions. Investing in any stock carries risks and it is important to research the company’s fundamentals before making any decisions. VI App makes this process much simpler by providing investors with an easy to access overview of the risks associated with a particular stock. With this information, investors can make more informed decisions about whether or not to invest in a company. More…
VI Peers
The healthcare sector is competitive, and companies are always vying for market share. Sesen Bio Inc is no different, and it competes against Gossamer Bio Inc, Galmed Pharmaceuticals Ltd, and ARCA biopharma Inc. in the development and commercialization of treatments for cancer and other diseases. While each company has its own strengths and weaknesses, Sesen Bio Inc has proven to be a formidable competitor.
– Gossamer Bio Inc ($NASDAQ:GOSS)
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of immunology, inflammation and oncology. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.
As of 2022, Gossamer Bio has a market cap of 1.17B and a ROE of -3124.66%. The company’s lead product candidates are GB001, GB002 and GB004, which are in clinical development for the treatment of autoimmune diseases, inflammatory diseases and cancer, respectively.
– Galmed Pharmaceuticals Ltd ($NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic solutions targeting liver diseases. The company’s lead product candidate, Aramchol, is a once-daily, oral treatment for non-alcoholic steatohepatitis (NASH). Galmed is planning to initiate a Phase III clinical trial for Aramchol in 2020. The company has a market cap of 9.04M as of 2022 and a Return on Equity of -111.62%.
– ARCA biopharma Inc ($NASDAQ:ABIO)
ACRA biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of cancer and other diseases. The company has a market cap of 29.54M as of 2022 and a Return on Equity of -22.71%. ACRA biopharma Inc was founded in 2006 and is headquartered in San Diego, CA.
Summary
Investment analysts have rated Sesen Bio Inc stock as a “Hold” despite the stock’s 1.96% loss this week and 43.82% drop over the last year. News coverage of the stock is mainly mixed, but investors should take note of the company’s performance before making any decisions. Analysts recommend taking a close look at Sesen Bio and its financials before investing, and to be aware of any potential risks that may come with the stock. It is important to do your own research and weigh the pros and cons of any investment decision before committing.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
